The FDA announced the approval of Afrezza (insulin human; MannKind) Inhalation Powder for type 1 and type 2 diabetes.
The FDA has found no clear evidence of increased cardiovascular risks associated with olmesartan medoxomil in patients with diabetes.
The FDA now requires a general warning in the drug labeling of all approved testosterone products regarding the risk of venous blood clots.
Many patients with adrenal incidentaloma may not receive the necessary care for their condition.
Levels of parathyroid hormone (PTH) should be considered when evaluating the effect of vitamin D status on glucose metabolism.
Lenvatinib, a new TKI inhibitor, delays disease progression and shows promising clinical efficacy against differentiated radioiodine-resistant thyroid cancer.